Novo Nordisk filed for FDA approval of CagriSema (the cagrilintide plus semaglutide combination) in late 2025, but the standalone compound has not been submitted for approval
Side effects include headache, insomnia, mood changes, nausea, and acne
Epithalon appears in Peptides UK catalogues as a single lyophilised research peptide, an acetate-associated material or a component within products marketed around sleep and longevity
Acetylcysteine monograph BNF
Cieri-Hutcherson NE, Jaenecke A, Bahia A, et al
Patients allege they were never warned of a potential association between Ozempic and other GLP-1 drugs , rapid metabolic or blood pressure changes, and optic nerve injury, despite emerging reports and post-marketing safety signals